This page is not the official website. Generated by AI, does not constitute any advice. If needed, please click here to visit the corresponding official website.

An Innovator of rAAV Technology

Pioneering Gene Therapy. Committed to Advancing Human Health.

Frontera Therapeutics is a clinical-stage biotech company dedicated to bringing innovative, high-quality, affordable rAAV gene therapies to patients worldwide. With a world-class team and cutting-edge platforms, we're addressing unmet needs in ophthalmology, hematology, and cardiology.

Explore Our Pipeline

About Frontera Therapeutics

Frontera is a clinical-stage biotechnology company with a mission to transform lives through gene therapy. Backed by top-tier academic and industrial experts and leading venture capital institutions, we are advancing a robust pipeline of recombinant adeno-associated virus (rAAV) therapies.

Our programs target serious diseases in ophthalmology, hematology, and cardiology. Several have entered or completed Phase II clinical trials, demonstrating best-in-class potential with strong competitive advantages in safety, efficacy, and manufacturability.

  • Clinical-stage rAAV gene therapy innovator
  • Dual R&D centers in Boston and Shanghai
  • GMP manufacturing in Suzhou, China
Frontera Research Lab

Innovative Technology Platforms

Frontera has developed two proprietary platforms that power our gene therapy pipeline: EXACTE™ for vector design and AAVANCE™ for scalable, high-yield manufacturing.

R&D Technology Platform (EXACTE™)

EXACTE Platform

AAV Vector Modification and Screening: Through rational design and in vitro/in vivo screening, we've developed novel rAAV capsid variants with enhanced tissue targeting, high transduction efficiency, and low immunogenicity.

Gene Expression Cassette Optimization: We optimize rAAV vectors and gene-of-interest (GOI) sequences to improve protein expression, enhance tissue specificity, and reduce immune responses.

Our platform enables rapid development of next-generation vectors with superior performance across multiple therapeutic areas.

Learn More on Official Site →

Production Technology Platform (AAVANCE™)

AAVANCE Platform

Based on the Sf9 insect cell expression system, AAVANCE™ delivers large-scale, high-yield, low-cost GMP production of rAAV vectors.

Our optimized purification process achieves empty capsid levels below 5%, significantly enhancing product safety and setting a new industry benchmark.

We've established a full-spectrum quality control and assurance system compliant with regulatory standards in the U.S., EU, and China.

Learn More on Official Site →

Our Clinical Pipeline

Advancing innovative gene therapies across ophthalmology, hematology, and cardiology.

OPHTHALMOLOGY

FT-001

Leber Congenital Amaurosis Type 2 (LCA2)

Regulatory Designation: CDE Breakthrough
Phase 2
OPHTHALMOLOGY

FT-002

X-Linked Retinitis Pigmentosa (XLRP)

Regulatory Designation: FDA ODD, Fast Track
Phase 2
OPHTHALMOLOGY

FT-003

nAMD, DME, DR

Latest: IND cleared for Diabetic Retinopathy (2025)
Phase 1
OPHTHALMOLOGY

FT-023

nAMD, DME, DR

Status: IND Enabling
Preclinical
HEMATOLOGY

FT-004

Hemophilia B

Status: IND Enabling
Preclinical
HEMATOLOGY

FT-005

Hemophilia A

Status: Research
Discovery
CARDIOLOGY

FT-017

Hypertrophic Cardiomyopathy (HCM)

Latest: FDA & CDE Approved (2025)
Phase 1/2
CARDIOLOGY

FT-018

Arrhythmogenic Right Ventricular Cardiomyopathy (ARVC)

Status: Research
Discovery

Company News

April 28, 2025

FT-017 Gains FDA and CDE Approval

Pioneering gene therapy for Hypertrophic Cardiomyopathy advances into clinical development.

April 22, 2025

Frontera to Present at 2025 ARVO and ASGCT

Showcasing innovative gene therapy advances at major scientific conferences.

March 13, 2025

IND Clearance for FT-003 in Diabetic Retinopathy

Expanding pipeline in retinal diseases with new clinical authorization.

Join Us

Become a team member at the forefront of the gene therapy industry and help patients around the world.

Explore Career Opportunities

Contact Us

Boston R&D Center

+1 617-5467300

Shanghai Operation Center

+86 21-58206061

Suzhou Manufacturing Site

+86 512-85883110

Visit Official Website to Contact
China Quality Suppliers fobcompany.info

Notice for Buyers: If you are a buyer, the above information is generated by AI collection and does not constitute any advice. If necessary, please visit the corresponding official website.

For Domain Owners: If you are the domain owner and do not want to be included by fobcompany.info, please contact [email protected] via your corporate email to cancel. We will cancel your inclusion within 3 business days.

如果您是域名所有者 不想被fobcompany.info收录 请用企业邮箱联系[email protected] 取消收录 我们将在3个工作日取消您的收录

Service Request: If you are other domain and want to be included, please contact [email protected]

如果您是其他域名合作 也请联系[email protected]